Functional imaging studies of non-motoric manifestations of Parkinson's Disease

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 3, 2009, Pages

  Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

5 hydroxytryptamine (5 HT, serotonin); Amyloid; Cardiac sympathetic innervation; Cholinergic; Dementia; Depression; Impulse control disorders; Non motor complications; Noradrenalin; Pain; Positron emission tomography; REM sleep behaviour disorder

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; 6 FLUORODOPAMINE F 18; AMYLOID PROTEIN; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; HYDROXYEPHEDRINE C 11; LEVODOPA; RACLOPRIDE C 11; RADIOISOTOPE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANXIETY; ARTICLE; AUTONOMIC DYSFUNCTION; BEHAVIOR DISORDER; BRAIN BLOOD FLOW; BRAIN METABOLISM; CLINICAL FEATURE; COGNITIVE DEFECT; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DYSESTHESIA; FUNCTIONAL ASSESSMENT; HUMAN; MENTAL DISEASE; MOTOR DYSFUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PAIN THRESHOLD; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC INNERVATION;

AUTONOMIC NERVOUS SYSTEM DISEASES; BRAIN; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MENTAL DISORDERS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; REM SLEEP BEHAVIOR DISORDER; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 71849106367     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70771-0     Document Type: Article

References (41)

1. Minoshima S., Foster N.L., Sima A.A., Frey K.A., Albin R.L., and Kuhl D.E. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 50 3 (2001) 358-365
2. Asanuma K., Tang C., Ma Y., Dhawan V., Mattis P., Edwards C., et al. Network modulation in the treatment of Parkinson's disease. Brain 129 Pt 10 (2006) 2667-2678
3. Feigin A., Kaplitt M.G., Tang C., Lin T., Mattis P., Dhawan V., et al. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA 104 (2007) 19559-19564
4. Huang C., Mattis P., Tang C., Perrine K., Carbon M., and Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 34 2 (2007) 714-723
5. Huang C., Mattis P., Perrine K., Brown N., Dhawan V., and Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 70 16 Pt 2 (2008) 1470-1477
6. Dagher A., Owen A.M., Boecker H., and Brooks D.J. The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease. Brain 124 Pt 5 (2001) 1020-1032
7. Monchi O., Ko J.H., and Strafella A.P. Striatal dopamine release during performance of executive functions: A [(11)C] raclopride PET study. Neuroimage 33 3 (2006) 907-912
8. Sawamoto N., Piccini P., Hotton G., Pavese N., Thielemans K., and Brooks D.J. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 131 Pt 5 (2008) 1294-1302
9. 18F]fluorodopa positron emission tomographic study. Arch Neurol 57 (2000) 470-475
10. Bohnen N.I., Kaufer D.I., Ivanco L.S., Lopresti B., Koeppe R.A., Davis J.G., et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60 12 (2003) 1745-1748
11. Hilker R., Thomas A.V., Klein J.C., Weisenbach S., Kalbe E., Burghaus L., et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65 11 (2005) 1716-1722
12. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 3 (2004) 306-319
13. Maetzler W., Reimold M., Liepelt I., Solbach C., Leyhe T., Schweitzer K., et al. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 39 3 (2008) 1027-1033
14. Gomperts S.N., Rentz D.M., Moran E., Becker J.A., Locascio J.J., Klunk W.E., et al. Imaging amyloid deposition in Lewy body diseases. Neurology 71 12 (2008) 903-910
15. Edison P., Rowe C.C., Rinne J.O., Ng S., Ahmed I., Kemppainen N., et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79 12 (2008) 1331-1338
16. Leentjens A.F., van den A.M., Metsemakers J.F., Lousberg R., and Verhey F.R. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 18 4 (2003) 414-418
17. Schuurman A.G., van den A.M., Ensinck K.T., Metsemakers J.F., Knottnerus J.A., Leentjens A.F., et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 58 10 (2002) 1501-1504
18. Guttman M., Boileau I., Warsh J., Saint-Cyr J.A., Ginovart N., McCluskey T., et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol 14 5 (2007) 523-528
19. Boileau I., Warsh J.J., Guttman M., Saint-Cyr J.A., McCluskey T., Rusjan P., et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [(11)C]DASB. Mov Disord 23 (2008) 1776-1780
20. Albin R.L., Koeppe R.A., Bohnen N.I., Wernette K., Kilbourn M.A., and Frey K.A. Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab 28 3 (2008) 441-444
21. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 2 (2003) 197-211
22. Remy P., Doder M., Lees A., Turjanski N., and Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128 Pt 6 (2005) 1314-1322
23. Kaasinen V., Nurmi E., Bergman J., Eskola O., Solin O., Sonninen P., et al. Personality traits and brain dopaminergic function in Parkinson's disease. Proc Natl Acad Sci USA 98 23 (2001) 13272-13277
24. Kaasinen V., Nurmi E., Bergman J., Solin O., Kurki T., and Rinne J.O. Personality traits and striatal 6-[18F]fluoro-L-dopa uptake in healthy elderly subjects. Neurosci Lett 332 1 (2002) 61-64
25. Evans A.H., Pavese N., Lawrence A.D., Tai Y.F., Appel S., Doder M., et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59 5 (2006) 852-858
26. Steeves T.D., Miyasaki J., Zurowski M., Lang A.E., Pellecchia G., Van Eimeren T., et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C]raclopride PET study. Brain 132 Pt 5 (2009) 1376-1385
27. Albin R.L., Koeppe R.A., Chervin R.D., Consens F.B., Wernette K., Frey K.A., et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 55 9 (2000) 1410-1412
28. Hilker R., Razai N., Ghaemi M., Weisenbach S., Rudolf J., Szelies B., et al. [18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease. Clin Neurol Neurosurg 105 4 (2003) 262-269
29. Gilman S., Koeppe R.A., Chervin R.D., Consens F.B., Little R., An H., et al. REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA. Neurology 61 1 (2003) 29-34
30. Brefel-Courbon C., Payoux P., Thalamas C., Ory F., Quelven I., Chollet F., et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 20 12 (2005) 1557-1563
31. Goldstein D.S., Holmes C.S., Dendi R., Bruce S.R., and Li S.T. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 58 8 (2002) 1247-1255
32. Berding G., Schrader C.H., Peschel T., van den H.J., Kolbe H., Meyer G.J., et al. [N-methyl 11C]meta-Hydroxyephedrine positron emission tomography in Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 30 1 (2003) 127-131
33. Leyton M., Boileau I., Benkelfat C., Diksic M., Baker G., and Dagher A. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 27 6 (2002) 1027-1035
34. de la Fuente-Fernandez R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127 Pt 12 (2004) 2747-2754
35. Small D.M., Jones-Gotman M., and Dagher A. Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. Neuroimage 19 4 (2003) 1709-1715
36. de la Fuente-Fernandez R., Ruth T.J., Sossi V., Schulzer M., Calne D.B., and Stoessl A.J. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293 5532 (2001) 1164-1166
37. de la Fuente-Fernandez R., Schulzer M., and Stoessl A.J. Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry 56 2 (2004) 67-71
38. Strafella A.P., Ko J.H., and Monchi O. Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation. Neuroimage 31 4 (2006) 1666-1672
39. Schenck C.H., Bundlie S.R., and Mahowald M.W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46 2 (1996) 388-393
40. Postuma R.B., Gagnon J.F., Vendette M., Fantini M.L., Massicotte-Marquez J., and Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology (2009)
41. Raffel D.M., Koeppe R.A., Little R., Wang C.N., Liu S., Junck L., et al. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med 47 11 (2006) 1769-1777